Intellia Therapeutics (NTLA) Leases (2019 - 2025)
Intellia Therapeutics (NTLA) has disclosed Leases for 7 consecutive years, with $106.0 million as the latest value for Q4 2025.
- On a quarterly basis, Leases fell 51.68% to $106.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $106.0 million, a 51.68% decrease, with the full-year FY2025 number at $106.0 million, down 51.68% from a year prior.
- Leases was $106.0 million for Q4 2025 at Intellia Therapeutics, down from $117.9 million in the prior quarter.
- In the past five years, Leases ranged from a high of $219.3 million in Q4 2024 to a low of $1.4 million in Q2 2021.
- A 5-year average of $101.1 million and a median of $108.2 million in 2024 define the central range for Leases.
- Peak YoY movement for Leases: plummeted 94.03% in 2021, then soared 5169.64% in 2022.
- Intellia Therapeutics' Leases stood at $79.1 million in 2021, then soared by 68.15% to $133.1 million in 2022, then decreased by 13.3% to $115.4 million in 2023, then soared by 90.07% to $219.3 million in 2024, then crashed by 51.68% to $106.0 million in 2025.
- Per Business Quant, the three most recent readings for NTLA's Leases are $106.0 million (Q4 2025), $117.9 million (Q3 2025), and $129.0 million (Q2 2025).